Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Neuro Oncol 2000 2(2):71-79; DOI:10.1215/15228517-2-2-71
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fults, D.
Right arrow Articles by Pedone, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Duke University Press

Tumor Biology

Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas

Dan Fults2 and Carolyn Pedone

Department of Neurosurgery and Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84132

2 Address correspondence and reprint requests to Dan Fults, Department of Neurosurgery, University of Utah Health Sciences Center, Salt Lake City, UT 84132.

Abstract

PTEN/MMAC1 (phosphatase and tensin homolog/mutated in multiple advanced cancers 1) is a tumor suppressor gene, the inactivation of which is an important step in the progression of gliomas to end-stage glioblastoma multiforme. We examined the distribution of PTEN protein in 49 primary human gliomas by immunocytochemistry using polyclonal antibodies that we raised against PTEN-glutathione S-transferase fusion proteins expressed in Escherichia coli. The study group consisted of 6 low-grade astrocytomas, 7 anaplastic astrocytomas, 21 glioblastomas multiforme, 4 low-grade oligodendrogliomas, 6 malignant oligodendrogliomas, and 5 malignant mixed oligoastrocytomas. For each tumor, we determined the percentage of tumor cells showing PTEN immunoreactivity in the most cellular regions of the tumor specimen. In both astrocytomas and oligodendrogliomas, there was an inverse relationship between the percentage of PTEN+ cells and malignancy grade, consistent with a role for PTEN as a tumor suppressor gene, the expression of which declines during glioma progression. In nonneoplastic tissue, PTEN was expressed in human fetal brain at 16, 23, and 27 weeks' gestation, but not in adult brain, indicating that PTEN is developmentally regulated in the CNS. In 21 glioblastomas multiforme, we correlated PTEN protein expression with PTEN gene sequence. Although PTEN-mutant tumors showed significantly diminished PTEN protein expression compared with wild-type cases, suppressed expression of PTEN is more prevalent than predicted from mutation frequencies.




This article has been cited by other articles:


Home page
Neuro OncolHome page
C. B. Knobbe, A. Merlo, and G. Reifenberger
Pten signaling in gliomas
Neuro-oncol, July 1, 2002; 4(3): 196 - 211.
[Abstract] [PDF]




  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2000 by Society for Neuro-Oncology